• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
App Store Download on the App Store Google Play GET IT ON Google Play

Get The App

App Store Download on the App Store Google Play GET IT ON Google Play
Krystal Biotech, Inc. (KRYS) Stock Price, News & Analysis

Krystal Biotech, Inc. (KRYS) Stock Price, News & Analysis

Currency in USD Disclaimer

$190.54

$8.25

(4.53%)

Day's range
$182.02
Day's range
$191.27
50-day range
$163.66
Day's range
$207.84
  • Country: US
  • ISIN: US5011471027
52 wk range
$99
Day's range
$219.34
  • CEO: Mr. Krish S. Krishnan M.B.A., M.S.
  • Website: Visit Site


We are preparing, please wait

1 Hour 1 Day 1 Week 1 Year Advanced Chart
Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 34.94
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (KRYS)
  • Company Krystal Biotech, Inc.
  • Price $190.54
  • Changes Percentage (4.53%)
  • Change $8.25
  • Day Low $182.02
  • Day High $191.27
  • Year High $219.34

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/24/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $205.50
  • High Stock Price Target $220.00
  • Low Stock Price Target $133.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.18
  • Trailing P/E Ratio 75.42
  • Forward P/E Ratio 75.42
  • P/E Growth 75.42
  • Net Income $10.93 M

Income Statement

Quarterly

Annual

Latest News of KRYS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

View ALL
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Krystal Biotech, Inc. Frequently Asked Questions

  • What were the earnings of KRYS in the last quarter?

    In the last quarter Krystal Biotech, Inc. earnings were on Monday, November, 4th. The Krystal Biotech, Inc. maker reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.01.

  • What is the Krystal Biotech, Inc. stock price today?

    Today's price of Krystal Biotech, Inc. is $190.54 — it has increased by +4.53% in the past 24 hours. Watch Krystal Biotech, Inc. stock price performance more closely on the chart.

  • Does Krystal Biotech, Inc. release reports?

    Yes, you can track Krystal Biotech, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Krystal Biotech, Inc. stock forecast?

    Watch the Krystal Biotech, Inc. chart and read a more detailed Krystal Biotech, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Krystal Biotech, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Krystal Biotech, Inc. stock ticker.

  • How to buy Krystal Biotech, Inc. stocks?

    Like other stocks, KRYS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Krystal Biotech, Inc.'s EBITDA?

    Krystal Biotech, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Krystal Biotech, Inc.’s financial statements.

  • What is the Krystal Biotech, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.2156255547, which equates to approximately 21.56%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Krystal Biotech, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Krystal Biotech, Inc.'s financials relevant news, and technical analysis. Krystal Biotech, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Krystal Biotech, Inc. stock currently indicates a “sell” signal. For more insights, review Krystal Biotech, Inc.’s technical analysis.

  • A revenue figure for Krystal Biotech, Inc. for its last quarter?

    Krystal Biotech, Inc. published it's last quarterly revenues at $83.84 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

or
download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Sign Up With Email Address
or
google app download Continue with Google ios app download Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.